Male patients require higher optimal effect-site concentrations of propofol during i-gel insertion with dexmedetomidine 0.5 關g/kg by 源�吏��쁺
RESEARCH ARTICLE Open Access
Male patients require higher optimal effect-
site concentrations of propofol during i-gel
insertion with dexmedetomidine 0.5 μg/kg
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Abstract
Background: The pharmacokinetics and pharmacodynamics of an anesthetic drug may be influenced by gender.
The purpose of this study was to compare effect-site half maximal effective concentrations (EC50) of propofol in
male and female patients during i-gel insertion with dexmedetomidine 0.5 μg/kg without muscle relaxants.
Methods: Forty patients, aged 20–46 years of ASA physical status I or II, were allocated to one of two groups by
gender (20 patients per group). After the infusion of dexmedetomidine 0.5 μg/kg over 2 min, anesthesia was
induced with a pre-determined effect-site concentration of propofol by target controlled infusion. Effect-site EC50
values of propofol for successful i-gel insertion were determined using the modified Dixon’s up-and-down method.
Results: Mean effect-site EC50 ± SD of propofol for successful i-gel insertion was significantly higher for men than
women (5.46 ± 0.26 μg/ml vs. 3.82 ± 0.34 μg/ml, p < 0.01). The EC50 of propofol in men was approximately 40 % higher
than in women. Using isotonic regression with a bootstrapping approach, the estimated EC50 (95 % confidence interval)
of propofol was also higher in men [5.32 (4.45–6.20) μg/ml vs. 3.75 (3.05–4.43) μg/ml]. The estimated EC95 (95 %
confidence interval) of propofol in men and women were 5.93 (4.72–6.88) μg/ml and 4.52 (3.02–5.70) μg/ml, respectively.
Conclusions: During i-gel insertion with dexmedetomidine 0.5 μg/kg without muscle relaxant, male patients had higher
effect-site EC50 for propofol using Schnider’s model. Based on the results of this study, patient gender should be
considered when determining the optimal dose of propofol during supraglottic airway insertion.
Trial registration: ClinicalTrials.gov identifier: NCT02268656. Registered August 26, 2014.
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Background
The i-gel airway is a single-use supra-glottic airway de-
vice. It was designed to fit peri-laryngeal structures and
has an anatomically designed cuff filled with a medical
grade thermoplastic elastomer gel. I-gel has been re-
ported to have several potential advantages, such as, eas-
ier insertion and less tissue compression, over other
supra-glottic airways with an inflatable cuff [1, 2].
Target controlled infusion (TCI) of propofol is
widely used for supra-glottic airway insertion without
neuromuscular blockade [3–5]. However, to obtain
sufficient anesthetic depth to decrease airway reactiv-
ity, the effect-site concentration of propofol should be
increased to a level that may lead to hypotension and
bradycardia [3–5]. To avoid such complications, opioids
or α2-agonistsis are concomitantly used as adjuvants
during anesthesia induction [5–8]. Dexmedetomidine is a
highly selective, short-acting α2-agonist with dose-
dependent analgesic, sedative, and anxiolytic effects. Jang
et al. [5] reported that preoperative dexmedetomidine
infusion of 1 μg/kg decreased the effect-site half maximal
effective concentration (EC50) of propofol by 53 % for
successful i-gel insertion without muscle relaxants in male
patients.
The pharmacokinetics and pharmacodynamics of
anesthetic drugs may be influenced by gender [9], and
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previous studies have reported that male patients require
significantly higher doses of propofol for loss of con-
sciousness than female patients during anaesthetic in-
duction [10, 11]. The purpose of this study was to
compare effect-site EC50 values of propofol in male and
female patients during i-gel insertion with dexmedeto-
midine 0.5 μg/kg without muscle relaxants. We hypothe-
sized that male patients would require higher effect-site
EC50 for successful i-gel insertion with dexmedetomi-
dine pretreatment.
Methods
This study was approved by the Institutional Review
Board of Gil Medical Center (IRB no. GCIRB 2014–153)
and registered at ClinicalTrials.gov (NCT 02268656).
Written informed consent was obtained from all patients.
Subjects
Forty patients aged 20–46 years of ASA physical status I
or II undergoing minor surgery (duration of 1–2 h) were
enrolled in the study. Patients were allocated to male or
female groups (20 patients per group). Patients were ex-
cluded if they had a predicted difficult airway, a recent
upper respiratory infection, unstable teeth, reactive airway
disease, or were obese (body mass index > 30 kg/m2).
Anesthesia and monitoring
Patients were not premedicated. After arrival in the operat-
ing theatre, electrocardiogram, pulse oximetry, automatic
non-invasive blood pressure, and bispectral index (BIS) (BIS
VISTATM monitor, four electrode sensor; Aspect Medical
Systems, Norwood, MA, USA) were monitored. For pre-
oxygenation, 100 % oxygen was administered for 3 min.
Target effect site concentration of propofol
Before anesthetic induction, dexmedetomidine 0.5 μg/kg
was infused for 2 min as described previously [12]. One
minute later, lidocaine 30 mg injection was followed by
propofol infusion using a TCI pump (Orchestra;
Fresenius-Vial, Brezins, France) and Schnider’s pharma-
cokinetic model for propofol [13]. If necessary, ventila-
tion was assisted manually to maintain an end-tidal CO2
tension between 30 and 35 mmHg. Five minutes after
propofol infusion, an i-gel airway (Intersurgical Ltd,
Wokingham, Berkshire, UK) was inserted after confirm-
ing target concentration and a BIS score below 60. One
experienced anesthesiologist inserted an i-gel using a
standard technique. After placing the patient in the
sniffing position (head extended and neck flexed), the
chin was gently pressed down and a lubricated i-gel was
inserted gently towards the hard palate until resistance
was felt. I-gel size was chosen according to patient
weight; #3 for a weight of 30–60 kg and #4 for a weigh-
ing of 50–90 kg.
Target effect-site concentration of propofol for the first
patient in each group was set at 5 μg/ml. Target effect-
site concentrations of propofol for the next patients
were determined by increasing or decreasing target
effect-site concentrations (0.5 μg/ml as a step size) ac-
cording to the response of the previous patient using the
modified Dixon’s up and down sequential method [14].
Successful i-gel insertion was defined as proper move-
ment of the chest and a continual end-tidal CO2 tension
wave (without air leakage) at a peak airway pressure of
<10 cmH2O. Insertion failure was defined as difficult
mouth opening, gagging, coughing, laryngeal spasm, and
signs of irritable body movements. In addition, if a pa-
tient showed an inadequate anesthetic level, such as, in-
tact eyelid reflex or a high BIS score of above 60,
insertion was regarded as having failed, and additional
propofol was administered. The physician that con-
ducted and evaluated insertion conditions was unaware
of propofol effect-site concentration. A single assess-
ment was obtained from each patient as whether inser-
tion was successful or not. Only, the result of the first
attempt was used for the analysis. After the assessment
of ‘success’ or ‘failure’, the further anesthesia induction
and maintenance were performed based on clinical need.
BIS score and hemodynamic data were measured at
baseline (T0), after dexmedetomidine administration
(T1), immediately before (T3) and 1 min after (T4) i-gel
insertion. Bradycardia was defined as a decrease of >
30 % from baseline or a heart rate (HR) of < 45 beats/
min persisting for more than 30 s and was treated with
intravenous atropine 0.5 mg. Hypertension was defined
as an increase of >20 % from baseline or a mean arterial
pressure (MAP) of > 120 mmHg and was treated with
intravenous nicardipine 300 μg.
According to Dixon’s up-and-down method, the stop-
ping rule required at least six pairs of ‘success’ and ‘failure’
[14], and data from seven independent pairs of patients
were collected for this study. The effect-site EC50 of pro-
pofol during i-gel insertion was defined as the mean of
midpoint concentrations of all independent pairs of pa-
tients after seven crossover points were obtained in each
group. The data were also subjected to isotonic regression
analysis for calculations of EC50 and EC95 with the 95 %
confidence intervals (CI) in each group [14]. An adjusted
response probability was easily calculated by the pooled-
adjacent-violators algorithm (PAVA) and the CI was esti-
mated by a bootstrapping approach [15, 16]. If the value
of EC50 did not overlap at the level of 83 % CI, the null
hypothesis of equal concentration could be rejected as a
type I error of 0.05 [17].
Statistics
Results are reported as means ± standard deviations (SDs),
median (ranges), or as numbers of patients. Statistical
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analysis was performed using the SPSS ver. 12.0 for Win-
dows (SPSS Inc., Chicago, IL). Demographic data were an-
alyzed using the independent t-test or the chi-square test
as appropriate. Hemodynamic and BIS data were analyzed
using repeated-measures ANOVA. Statistical significance
was accepted for p values of < 0.05.
Results
Twenty-patients were enrolled in each group. Patient
characteristics and causes of i-gel insertion failure are
listed in Table 1. Mean weight and height were signifi-
cantly higher in the male group (all p values < 0.01),
whereas group mean ages were similar. Insertion oc-
curred in 10 men and 9 women, and causes of failure
were not different in the two groups.
The up-and-down sequences in consecutive patients
are illustrated in Fig. 1. According to modified Dixon’s
up-and-down method, the effect-site EC50 (± SD) of
propofol for successful i-gel insertion was significantly
higher for men than women (5.46 ± 0.26 vs. 3.82 ± 0.34 μg/
ml, p < 0.01). By isotonic regression with bootstrapping
(Fig. 2), the estimated effect-site EC50 (83 % CI, 95 % CI) of
propofol was also higher in men [5.32 (4.60–6.02, 4.45–
6.20) vs. 3.75 (3.18–4.31, 3.05–4.43) μg/ml]. The effect-site
EC95 values (95 % CI) of propofol in the male and female
groups were 5.93 (4.72–6.88) μg/ml and 4.52 (3.02–5.70)
μg/ml, respectively. The actual mean doses infused over
5 min (from start of the infusion to the completion of i-gel
insertion) in men and women were 3.35 ± 0.81 mg/kg and
2.77 ± 0.41 mg/kg, respectively, and thus, actual mean dose
was also higher for men (p = 0.008).
BIS and hemodynamic data for successful i-gel inser-
tion are listed in Table 2. No significant intergroup dif-
ference in BIS, MAP, or HR was observed at any time
(all p values > 0.05). BIS decreased significantly in both
groups (both p < 0.01), but these change were similar in
the two groups (p = 0.969). Similarly, MAP and HR
changed significantly (both p < 0.001), and these changes
were also similar in the two groups (p = 0.35 and 0.95,
respectively). No laryngospasm or desaturation (defined
as SpO2 < 90 %) occurred during the study. After dexme-
detomidine administration, one male patient had brady-
cardia, which was treated with atropine, and one female
had hypertension, which was treated with nicardipine.
Discussion
This study demonstrates that during i-gel insertion with
dexmedetomidine pretreatment, male patients require sig-
nificantly higher effect-site EC50 values of propofol using
Schnider’s model. The effect-site EC50 values of propofol
for successful i-gel insertion with dexmedetomidine 0.5 μg/
kg without muscle relaxants in male and female patients
were found to be 5.46 and 3.82 μg/ml, respectively.
There is growing interest in gender difference from
the pharmacokinetic and pharmacodynamic perspec-
tives. In the case of propofol, male patients have been
reported to have significantly longer recovery times than
female patients [18, 19], which supports the possibility
that women are less sensitive to propofol. However, for
loss of consciousness at induction, propofol require-
ments were found to be significantly greater for men
[10, 11]. A recent study by Fu et al. [20] reported the
menstrual cycle may influence EC50 for loss of con-
sciousness and that it was significantly lower in the lu-
teal phase than in the follicular phase. The authors
concluded that anesthetic effects might be influenced by
difference in progesterone levels [20]. To the best of our
knowledge, no study has previously reported a gender
effect on the EC50 of propofol with respect to supraglot-
tic airway insertion. The present study shows a gender
difference in effect-site EC50 of propofol for i-gel inser-
tion by the modified Dixon’s method and isotonic re-
gression analysis. Taken together, a female sex hormone-
induced gender difference in the pharmacodynamics of
propofol provides a possible explanation for our results.
Another possible explanation is that the suppression of
airway reactivity or cough reflex by anesthetics exhibits a
gender difference, because this suppression is one of the
most important aspects of achieving successful supraglottic
airway insertion without a neuromuscular blocking agent.
In an earlier study about remifentanil requirements for
cough suppression during emergence, it was reported that
its antitussive effect was achieved at a significantly higher
concentration in males than in females [21]. The authors
suggested that during anesthesia emergence anesthetic con-
centrations required for cough suppression may differ for
genders under similar clinical conditions. In an experimen-
tal study, it was shown male sex hormones might promote
reflex airway responsiveness and that there was a gender
Table 1 Patients Characteristics
Variables Male (n = 20) Female (n = 20)
Age (years) 35 ± 11 35 ± 9
Weight (kg) 70 ± 10 57 ± 8*
Height (cm) 171 ± 6 159 ± 7*
ASA physical status (I/II) 18/2 19/1
Cause of failure (n = 10) (n = 9)
Difficult mouth opening 2 0
Gross purposeful movement 6 5
Gagging 8 5
Coughing 3 0
Laryngospasm 0 0
Sedation failure 2 2
Values are represented as mean ± SD or numbers of patients. ASA, American
Society of Anesthesiologists. *p < 0.05, male vs. female
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disparity in terms of airway responsiveness to cholinergic
stimulation [22].
Opioid analgesics are frequently used adjuncts during
propofol anesthesia, and have been reported to exhibit
gender dependent pharmacodynamic properties [9]. How-
ever, no report has been issued on such dependencies for
dexmedetomidine. It has been reported the pharmacokin-
etics of dexmedetomidine are best described by a three-
compartment model, and that the addition of age, weight,
lean body mass, and body surface area do not improve the
predictive value of the model [23]. In addition, for
anesthetic interaction producing hypnosis and immobility,
propofol and opioids appear to act synergistically, whereas
propofol and clonidine seem to act additively [24]. Thus,
we selected dexmedetomidine as an anesthetic adjuvant,
and believe it is unlikely to have influenced the gender dif-
ference observed in the present study. The preoperative
dexmedetomidine dose of 0.5 μg/kg was chosen based on
the results of a previous study, which reported that the ef-
fective dose of dexmedetomidine in 50 % patients was
0.55 μg/kg during anesthetic induction with propofol
2 mg/kg [12]. As for the propofol dose sparing effect, a re-
cent study reported that dexmedetomidine 0.5ug/kg re-
duced the propofol dose required for anesthesia induction
[25]. Further studies are needed to elucidate the nature of
the pharmacodynamic interaction between propofol and
dexmedetomidine and its dependence on gender.
In the present study, propofol was infused using a TCI
pump (Orchestra; Fresenius-Vial, Brezins, France) using
Schnider’s pharmacokinetic model for propofol. Several
pharmacokinetic models are used for propofol, and the
most widely used are the Marsh, modified Marsh, and
Schnider models. Had a pharmacokinetic model other
than the Schnider model been applied in the present
study, undoubtedly different results would have been ob-
tained. It has been reported that when the Marsh model
Fig. 1 Consecutive effect-site concentration of propofol (Cepropofol) for i-gel insertion in male (upper) and female (lower) patients after preoperative
dexmedetomidine (0.5 μg/ml) administration. Horizontal lines represent the half maximal effective effect-site concentrations (EC50). Mean EC50 (± SD)
values in the male and female groups were 5.46 ± 0.26 and 3.82 ± 0.34 μg/ml, respectively (p < 0.01)
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is used, a high initial dose is required for anesthesia in-
duction and that this causes overshooting, which results
in a shorter loss of consciousness time and a lower esti-
mated effect-site propofol concentration than when the
Schnider model is used [26, 27]. In a previous study that
applied the Marsh model, actual measured propofol con-
centration was 40 % higher than estimated concentration
in men, but only a difference of 2 % was observed in
women, so the estimate was less accurate in men [28].
However, the Schnider model makes a correction for the
effect of body mass index, age and sex. The fact that
Schnider model already incorporates a gender difference
may make the result of study questionable. However, the
gender difference taken into account in Schnider model
is not likely to affect the result of this study since this
difference in clearance based on lean body mass is im-
portant when propofol is infused during maintenance of
anesthesia. This study encompass the induction period,
which concerns the sensitivity to loss of consciousness,
not the clearance of the drug from the system.
In this study, the optimal male and female doses were
analyzed using EC50 values determined using Dixon’s up
and down method, and because EC95 values are clinic-
ally significant, they were calculated by isotonic regres-
sion analysis. In the event, effect-site EC95 values (95 %
CI) of propofol in the male and female groups were
found to be 5.93 (4.72–6.88) μg/ml and 4.52 (3.02–5.70)
μg/ml, respectively, which were not significantly differ-
ent. We chose isotonic regression because progbit ana-
lysis is a parametric technique. In addition, isotonic
regression has a smaller bias and tighter CIs compared
to standard probit analysis [15].
The present study has several limitations that warrant
consideration. First, we did not measure propofol plasma
concentrations, but rather predicted propofol concentra-
tions using Schnider’s pharmacokinetic model [13], in
which time to peak effect and ke0 are 1.7 min and 0.46/
min, respectively [29]. To ensure equilibration between
Table 2 Hemodynamic and bispectral index data for successful
i-gel insertion
Group T0 T1 T2 T3
BIS Male (n = 10) 95 ± 3 92 ± 5 44 ± 13 43 ± 17
Female (n = 11) 94 ± 5 94 ± 5 43 ± 15 44 ± 14
MAP Male (n = 10) 100 ± 17 106 ± 15 90 ± 12 88 ± 10
Female (n = 11) 102 ± 18 117 ± 22 91 ± 12 95 ± 13
HR Male (n = 10) 67 ± 14 58 ± 8 60 ± 14 64 ± 13
Female (n = 11) 69 ± 13 61 ± 12 57 ± 10 61 ± 11
Values are represented as mean ± SD. BIS, bispectral index; MAP, mean arterial
blood pressure (mmHg); HR, heart rate (beats/min). T0, baseline value (before
anesthesia induction); T1, after dexmedetomidine administration; T2,
immediately before i-gel insertion; T3, 3 min after i-gel insertion
Fig. 2 Pooled-adjacent-violators algorithm (PAVA) response rate in male (unfilled square) and female (filled square) patients. EC50 (95 % CI) values in
male and female groups were 5.32 (4.45–6.20) and 3.75 (3.05–4.43) μg/ml, respectively, and corresponding EC95 (95 % CI) values were 5.93 (4.72–6.88)
and 4.52 (3.02–5.70) μg/ml, respectively. Isotonic regression showed the EC50 value was significantly higher in the male group than in the female group
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blood- and effect-site concentrations, the steady-state in-
fusion for propofol should be maintained for 15 min be-
fore giving a verbal command or administering other
drugs [30]. However, many studies on supraglottic air-
way insertion have used loss of consciousness (LOC)
time to enable prompt progress of surgery [31, 32]. In a
previous study, LOC time of 171.4 ± 70.9 s was reported
when 4 μg/ml of propofol was administered [33], and in
another study, in which an effective site target concen-
tration of 6 μg/ml of propofol was set, an induction time
(defined from propofol infusion commencement to the
completion of LMA insertion) of 146.9 ± 42.3 s was re-
ported [31]. Based on these reports, the present study
was conducted based on the assumption that 5 min of
infusion would induce LOC. Second, dexmedetomidine
preceded propofol only by about 3 min to minimize in-
duction time, and since dexmedetomidine takes 15 min
to achieve optimal effect, the EC50 of propofol may have
been different had a 15 min time lag been used between
dexmedetomidine and propofol. However, the effect of
this is in our opinions unlikely to influence the observed
gender-dependent dose difference. Third, this study was
not conducted using a double blind design because the re-
searcher that inserted the i-gel was aware of group iden-
tities. The researcher was only blinded to the concentration
of propofol but the information of a previous patient may
have affected the decision of the i-gel insertion status of the
next patient. Fourth, weights obvious differed in the two
study groups, and collinearity problems arise when an ex-
planatory variable (covariate), in this case weight, is not in-
dependent. However, since we used a TCI pump and the
Schnider model, which takes height, weight, and lean body
mass into account as covariates, we believe the effect of
weight difference was slight. Lastly, the menstrual cycle was
not checked in the female group. Since female sex hor-
mones may influence hypnotic drug dosage, further study
is needed to elucidate the effect of the menstrual cycle on
the EC50 of propofol.
Conclusion
During i-gel insertion with dexmedetomidine 0.5 μg/kg
without muscle relaxant, male patients were found to re-
quire a higher effect-site EC50 of propofol than female
patients using Schnider’s model. Based on the results of
this study, patient gender should be considered when
determining the optimal dose of propofol required for
supraglottic airway insertion.
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